Managed Access Program (MAP) to Provide Access to Nilotinib, for Patients With Hypereosinophilic Syndrome (HES)
Latest Information Update: 25 Sep 2021
At a glance
- Drugs Nilotinib (Primary)
- Indications Hypereosinophilic syndrome
- Focus Expanded access; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 14 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 06 Aug 2020 New trial record